X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VTX3232 is NLRP3 inflammasome inhibitor, small molecule drug candidate. It is currently being evaluated for the treatment of patients with parkinson's disease.
Lead Product(s): VTX3232
Therapeutic Area: Neurology Product Name: VTX3232
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
Ventyx currently intends to use the net proceeds from the proposed private placement to fund the clinical development of VTX002. It is being evaluated in Phase II clinical trial studies for the treatment of ulcerative colitis.
Lead Product(s): VTX002
Therapeutic Area: Gastroenterology Product Name: VTX002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 07, 2024
Details:
VTX002 is a peripherally-restricted, potent and selective, orally bioavailable small molecule modulator of the S1P1 receptor and being investigated for Patients with Moderate to Severe Plaque Psoriasis.
Lead Product(s): VTX958
Therapeutic Area: Dermatology Product Name: VTX958
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
VTX002 is a peripherally-restricted, potent and selective, orally bioavailable small molecule modulator of the S1P1 receptor and being investigated for Ulcerative Colitis.
Lead Product(s): VTX002
Therapeutic Area: Gastroenterology Product Name: VTX002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
VTX002 is a peripherally-restricted, potent and selective, orally bioavailable small molecule modulator of the S1P1 receptor and being investigated for Ulcerative Colitis. VTX958, an oral, selective, allosteric TYK2 inhibitor used for treatment of Plaque Psoriasis.
Lead Product(s): VTX002
Therapeutic Area: Gastroenterology Product Name: VTX002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2023
Details:
The wide therapeutic window of VTX958 observed in our Phase 1 trial will allow us to explore a broad range of doses in Phase 2 trials, including doses designed to achieve biologic-like IC90 coverage of TYK2-mediated cytokines, such as IL-23.
Lead Product(s): VTX958
Therapeutic Area: Dermatology Product Name: VTX958
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
Ventyx intends to use the net proceeds from the proposed private placement, to fund the clinical development of VTX958, VTX002, VTX2735 and VTX3232, the preclinical development of other programs, research activities and working capital and other general corporate purposes.
Lead Product(s): VTX958
Therapeutic Area: Dermatology Product Name: VTX958
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Redmile Group
Deal Size: $176.6 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 19, 2022
Details:
VTX958 is an oral, selective allosteric inhibitor of tyrosine kinase 2 (TYK2). TYK2 regulates both innate and adaptive immunity by mediating IFNα, IL-12 and IL-23 signaling.
Lead Product(s): VTX958
Therapeutic Area: Dermatology Product Name: VTX958
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Details:
VTX2735 is the first of Ventyx’s two NLRP3 development candidates to enter the clinic. The second candidate, VTX3232, is an orally bioavailable, CNS-penetrant NLRP3 inhibitor and belongs to a structurally distinct chemical series than VTX2735.
Lead Product(s): VTX2735
Therapeutic Area: Cardiology/Vascular Diseases Product Name: VTX2735
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
VTX002 is a peripherally-restricted, potent and selective, orally bioavailable small molecule modulator of the S1P1 receptor. It sequesters lymphocytes in the lymph nodes, resulting in fewer immune cells in the circulating blood to exacerbate inflammation.
Lead Product(s): VTX002
Therapeutic Area: Gastroenterology Product Name: VTX002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
